/
Lisata Therapeutics, Inc. (together with its subsidiaries, the Company ) is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other serious diseases. Our investigational product, certepetide (formerly known as LSTA1 or CEND-1), is designed to activate a novel uptake pathwa…
The business is unprofitable at the operating level (-10711.18% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 83.0% YoY. Margins deteriorated 8470.3pp alongside, both lines moving the wrong way.
ROIC dropped from -45.30% to -64.56%, capital efficiency is deteriorating. Negative free cash flow of -$16M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$170K
▼ -83.0% YoY
Net Income (TTM)
-$16M
▲ +17.0% YoY
Op. Margin
-10178.82%
▼ -8470.3pp YoY
ROIC
-85.13%
▼ -19.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$14M
▲ +17.5% YoY
Op. Cash Flow (TTM)
-$14M
▲ +17.6% YoY
Net Debt
-$13M
Net Cash Position
Cash & Equiv.
$13M
Continue Research